- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07679256
Integrated Digital and Neurogenic Exosome Biomarkers for Early Diagnosis of Parkinson's Disease: Development and Application
25 juni 2026 uppdaterad av: Fujian Medical University Union Hospital
Based on the high-quality Parkinson's disease cohort population and biological sample database in the early stage of the team, multi-dimensional intelligent wearable device technology and machine learning were used to screen and classify digital biomarkers in the prodromal PD cohort, early PD cohort and healthy population cohort.
Using peptide nanoprobes, metabolomics and Simoa technology to find the pathological molecular biomarkers of high-purity blood neurogenic exosomes in the prodromal stage of PD cohort, early PD cohort and healthy population cohort, and conduct classification and combination study.
The association analysis was used to explore the specific internal relationship between digital biomarkers and neurogenic exosome molecular biomarkers, to explore the potential relationship between the two types of biomarkers, and to further apply machine learning methods to establish a fusion model for early diagnosis of PD including markers related to digital phenotype and pathological molecular mechanism, and to verify it clinically.
The research results of this project are expected to bring new strategies for the early diagnosis of PD biomarkers, provide theoretical support for clinical transformation, and have important clinical significance for achieving the goal of early diagnosis and early treatment.
Studieöversikt
Status
Rekrytering
Betingelser
Studietyp
Observationell
Inskrivning (Beräknad)
700
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studiekontakt
- Namn: qinyong ye
- Telefonnummer: 13365910205
- E-post: unionqyye@163.com
Studieorter
-
-
Fujian
-
Fuzhou, Fujian, Kina, 350000
- Rekrytering
- Department of Neurology, Fujian Institute of Geriatrics, Fujian Medical University Union Hospital
-
Kontakt:
- Department of Neurology, Fujian Institute of Geriatrics, Fujia Department of Neurology, Fujian Institute of Geriatrics, Fujia
- Telefonnummer: +86 591 8621 8329
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Ja
Testmetod
Sannolikhetsprov
Studera befolkning
This study comprises a combined retrospective and prospective cohort of patients with idiopathic Parkinson's disease (PD), selected from the PD registry database maintained by our team at Fujian Medical University Union Hospital.
The study population includes individuals who meet all of the following criteria: (1) diagnosed with idiopathic PD based on the Movement Disorder Society (MDS) clinical diagnostic criteria; (2) Hoehn-Yahr (H-Y) stage ≤ 2.0 during off-medication periods; and (3) Mini-Mental State Examination (MMSE) score > 24 points.
Eligible participants will be identified from the existing database for retrospective data collection, while prospective follow-up data will be collected for the same cohort to enable comprehensive longitudinal analyses.
Beskrivning
Inclusion Criteria:
1. Healthy Control Group
- No severe mental illness;
- Mini-Mental State Examination (MMSE) score >24 points; 2. Prodromal PD Group
- Meets the diagnostic criteria for rapid eye movement sleep behavior disorder;
- Has no severe mental disorders;
- Mini-Mental State Examination (MMSE) score is greater than 24 points. 3. Early PD Group
(1) Diagnosed with idiopathic Parkinson's disease based on the MDS clinical diagnostic criteria ; (3) Hoehn-Yahr (H-Y) stage <=2.0 during off-medication periods; (4) Mini-Mental State Examination (MMSE) score >24 points;
Exclusion Criteria:
- Presence of mental, cognitive, or psychological disorders, unable to sign informed consent;
- Presence of other diseases affecting walking distance, such as lower limb joint lesions, spinal lesions, neurological disorders, or severe cardiopulmonary diseases;
- Presence of intracranial structural changes, cerebrovascular disease, or other neurological disorders;
- Presence of tumors, severe liver or kidney dysfunction (indicators exceeding three times the normal value), or other conditions that significantly impact health;
- Claustrophobia or presence of implants affecting MRI scanning.
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
|---|
|
Hälsokontroll
|
|
PD prodromal group
|
|
Early PD group
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Mini-mental State Examination
Tidsram: baseline
|
Mini-Mental State Examination (MMSE) is a 30-item cognitive screening tool assessing orientation, memory, attention, calculation, and language, with total scores ranging from 0 to 30.
Higher scores indicate better cognitive function.
Scores ≥27 generally indicate normal cognition, while lower scores suggest varying degrees of impairment, with cutoffs adjusted for education and age.
|
baseline
|
|
Montreal Cognitive Assessment
Tidsram: baseline
|
Montreal Cognitive Assessment (MoCA) is a 10-15 minute screening tool covering 8 cognitive domains through 12 tasks, with total scores ranging from 0 to 30.
Higher scores indicate better cognitive function.
Scores ≥26 are generally considered normal, with a 1-point adjustment for education ≤12 years; scores <26 suggest possible cognitive impairment.
|
baseline
|
|
The 39-Item Parkinson's Disease Questionnaire
Tidsram: baseline
|
Non-Motor Symptoms Scale (NMSS) assesses frequency and severity of non-motor symptoms across all stages of Parkinson's disease, covering autonomic, affective, cognitive, sleep, and other domains.
Total scores range from 0 to 360.
Higher scores indicate worse outcome (greater symptom burden).
|
baseline
|
|
Hamilton Depression Rating Scale
Tidsram: baseline
|
Hamilton Depression Rating Scale (HAM-D) is a clinician-rated instrument assessing depression severity across multiple dimensions including mood, somatic symptoms, anxiety, and sleep disturbance.
The 17-item version (HAM-D17) yields total scores ranging from 0 to 52.
Higher scores indicate worse outcome (greater depressive symptom severity), with scores ≥23 indicating very severe depression.
|
baseline
|
|
hoehn-yahr stage
Tidsram: baseline
|
Hoehn and Yahr Scale (HY) is a clinician-rated instrument assessing clinical severity and disease staging in Parkinson's disease.
Staging ranges from 0 (no symptoms) to 5 (severe disability requiring full dependence).
Higher stages indicate worse outcome (more advanced disease with greater functional impairment), primarily based on postural instability and disability.
|
baseline
|
|
Movement Disorder Society-Sponsored Revision Of The Unified Parkinson's Disease Rating Scale
Tidsram: baseline
|
Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is a comprehensive instrument assessing Parkinson's disease across four parts: non-motor symptoms, activities of daily living, motor symptoms, and complications.
Total scores range from 0 to 260 (Part I: 0-52, Part II: 0-52, Part III: 0-132, Part IV: 0-24).
Higher scores indicate worse outcome (greater impairment).
|
baseline
|
|
Wearable devices measure gait parameters
Tidsram: baseline
|
Wearable Device System (GYENNO MATRIX) is a 10-sensor system sampling at 100 Hz to capture 3D angular velocity, acceleration, and geomagnetic field data.
It extracts gait parameters (step length, stride, gait cycle) and detects postural transitions (standing, sitting, turning).
|
baseline
|
|
Sniffin' Sticks 12
Tidsram: baseline
|
Sniffin' Sticks 12 (SS-12) is a brief olfactory screening test assessing odor identification ability using 12 pen-like odor pens.
Total scores range from 0 to 12, based on the number of correctly identified odors.
Higher scores indicate better outcome (superior olfactory function).
It is widely used for early Parkinson's disease screening and cognitive disorder assessment.
|
baseline
|
|
REM sleep behavior disorderscreening questionnaire
Tidsram: baseline
|
REM Sleep Behavior Disorder Screening Questionnaire (RBDSQ) is a 10-item self-rated scale screening for REM sleep behavior disorder, covering dream content, dream-enactment behaviors, injuries, and neurological conditions.
Total scores range from 0 to 13.
Higher scores indicate worse outcome (greater likelihood of abnormality), with scores ≥5 considered abnormal.
|
baseline
|
|
Parkinson's disease sleep scale
Tidsram: baseline
|
Parkinson's Disease Sleep Scale (PDSS) is a 15-item scale assessing sleep disturbances in Parkinson's disease, covering nighttime quality, sleep onset, maintenance, limb discomfort, dreaming, hallucinations, nocturia, and daytime sleepiness.
Total scores range from 0 to 150 (0-10 per item).
Higher scores indicate better outcome (fewer or less severe sleep problems).
|
baseline
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Faktisk)
1 januari 2024
Primärt slutförande (Beräknad)
31 december 2027
Avslutad studie (Beräknad)
31 december 2027
Studieregistreringsdatum
Först inskickad
22 december 2025
Först inskickad som uppfyllde QC-kriterierna
25 juni 2026
Första postat (Faktisk)
1 juli 2026
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
1 juli 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
25 juni 2026
Senast verifierad
1 december 2025
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 2026KY647
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
NEJ
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .